<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46728">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01676727</url>
  </required_header>
  <id_info>
    <org_study_id>V1 04JUN2012</org_study_id>
    <nct_id>NCT01676727</nct_id>
  </id_info>
  <brief_title>ADVANCE Direct Aortic</brief_title>
  <acronym>ADVANCE DA</acronym>
  <official_title>CoreValve® ADVANCE Direct Aortic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Norway: Regional Ethics Commitee</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>Italy: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to collect data regarding the clinical utility, safety and
      performance of the Medtronic CoreValve® System for Transcatheter Aortic Valve Implantation
      (TAVI) in patients with severe symptomatic aortic valve stenosis for which treatment via
      direct aortic access (DA) is selected. As part of the study analysis, resource utilization
      together with the Quality of Life questionnaires data will provide an important input into
      cost effectiveness analysis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days post-implant</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)-Combined safety endpoint</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The combined safety endpoint is defined as a composite of:
All-cause mortality
All stroke
Life-threatening bleeding
Acute kidney injury—Stage 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)
High degree AV block requiring permanent pacemaker implantation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Valvular Heart Disease</condition>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic stenosis who are scheduled for an elective transcatheter
        aortic valve implantation and who are selected (e.g. because of an calcified femoral
        artery) to receive the CoreValve® device via direct aortic access.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe symptomatic aortic valve stenosis requiring treatment

          2. Acceptable candidate for elective treatment with the Medtronic CoreValve®  System
             according to the most recent version of the Medtronic CoreValve®  Instructions For
             Use

          3. 21 years of age or older

          4. Patient is willing and able to comply with all protocol-specified follow-up
             evaluations

          5. The patient or legal representative has been informed of the nature of the study and
             has consented to participate, and has authorized the collection and release of
             his/her medical information by signing a consent form (&quot;Patient Informed Consent
             Form&quot;)

          6. Patient will receive the CoreValve® device via direct aortic approach TAVI -

        Exclusion Criteria:

          1. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine,
             clopidogrel, nitinol, or sensitivity to contrast media which cannot be adequately
             pre-medicated

          2. Sepsis, including active endocarditis

          3. Recent myocardial infarction (&lt;30 days)

          4. Left ventricular or atrial thrombus by echocardiography

          5. Uncontrolled atrial fibrillation

          6. Mitral or tricuspid valvular insufficiency (&gt;grade II)

          7. Previous aortic valve replacement (mechanical valve or stented bioprosthetic valve)

          8. Evolutive or recent (within 6 months of implant procedure) cerebrovascular accident
             (CVA) or transient ischemic attack (TIA)

          9. Patients with:

               1. Vascular conditions that make insertion and endovascular access to the aortic
                  valve impossible, or

               2. Symptomatic carotid or vertebral arterial narrowing (&gt;70%) disease, or

               3. Thoracic aortic aneurysm in the path of delivery system

         10. Bleeding diathesis or coagulopathy

         11. Patient refuses blood transfusion

         12. Estimated life expectancy of less than 12 months unless TAVI is performed

         13. Creatine clearance &lt;20 mL/min

         14. Active gastritis or peptic ulcer disease

         15. Pregnancy or intent to become pregnant during study follow up

         16. Patient is participating in another trial that may influence the results of this
             study

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Moat, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Brompton Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Bruschi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda spedaliera Niguarda Ca' Granda Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gwenn Wetzels, PhD</last_name>
    <phone>+31 (0) 43 3566527</phone>
    <email>gwenn.wetzels@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maarten Hollander, MSc</last_name>
    <phone>+31 (0) 43 3566864</phone>
    <email>maarten.hollander@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nemocnice Podlesi Trinec</name>
      <address>
        <city>Trinec</city>
        <zip>739 61</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marian Branny, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Branny, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernard Chevalier, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romano Mauro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033 Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Philippe Verhoye, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herve Le Breton, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 CEDEX 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bertrand Marcheix, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Dumonteil, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hasan Bushnaq, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Bruder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karl Friedrich, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Eugen Hauptmann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda spedaliera Spedali Civili Di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frederica Ettori, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Coletti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda spedaliera Niguarda Ca' Granda Milano</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppe Bruschi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvio Klugmann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erwin Tan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guus Brueren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet HF</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gry Dahle, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bjorn Bendz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Śląskie Centrum Chorob Serca</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marian Zembala, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neil Moat, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon William Davies, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 29, 2012</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic valve Implantation</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
